| Name | Title | Contact Details |
|---|
Care New England Health System (CNE) and its member institutions—Butler Hospital, Women & Infants Hospital, Kent Hospital, Memorial Hospital, VNA of Care New England, The Providence Center and Care New England Wellness Center—are trusted organizations fueling the latest advances in medical research, attracting the nation`s top specialty-trained doctors, and honing renowned services and innovative programs to engage in the important discussions people need to have about their health. Backed by a broad range of services—primary care, surgery, cardiovascular care, oncology, psychiatry, behavioral health, newborn pediatrics and the full spectrum of women`s health services—CNE is reinventing the way health care is delivered, partnering with our patients to provide the best care possible while working to create a community of healthier people. To that end, we are committed to a culture of accountability, caring and teamwork. We called it ACT values. These values were not defined by senior management but through a comprehensive process with our employees who identified these values as tangible and important to the cohesiveness of the entire organization. They are embedded into everything we do, working with patients and their families, and with each other.
Cellenkos is an early stage clinical biotechnology company that focuses on cord blood-derived T-regulatory cellular therapies for the treatment of autoimmune diseases and inflammatory conditions. Cellenkos is founded on the technologies arising from the laboratory investigations of Simrit Parmar, M.D. Cellenkos` lead product CK0801 delivers clinically meaningful doses of allogeneic cord blood T-regulatory cells to overcome immune dysfunction.
Millennium Laboratories, a leader in the science of toxicology and pharmacogenetics, is transforming the way health care providers improve clinical outcomes. Millennium helps practitioners provide personalized care to patients in need through its patient-centered research and education initiatives and its ability to respond to evolving health care challenges with advanced technologies.
Delphinus Medical Technologies, Inc. is an innovation leader in advanced ultrasound development, introducing a dynamic new technique to image the breast with the use of sound and water. Delphinus is committed to creating improved imaging methods that assist medical professionals to better define and diagnose breast disease, while establishing a better patient experience that can be available for all women, regardless of age, without the concern of radiation or pain. Headquartered in Plymouth, MI, Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a ring transducer to transmit and receive ultrasound signals. Known as SoftVue™, three critical sound characteristics are measured and refined through proprietary algorithms, advancing this technology far beyond traditional b-mode ultrasound. By collecting and defining reflection, sound speed, and attenuation data in a 360° orientation, data are gathered and reconstructed in tomographic coronal planes, providing an enriched image set presented for cross-sectional review. SoftVue has received FDA clearance for diagnostic imaging purposes and is not intended for use as a replacement for screening mammography. Delphinus was formed in 2010 as a spin-out of Karmanos Cancer Institute [KCI] in Detroit, MI. Created by Peter Littrup, MD of Karmanos and Neb Duric, PhD of Wayne State University Detroit, MI the SoftVue technology presents a new imaging paradigm in breast disease assessment. Karmanos Cancer Institute has served as a primary investigational site for case collection and clinical studies. Delphinus holds numerous patents and proprietary assets for its innovative and scientifically-advanced works and is poised to usher in a new era of breast imaging.
Author of Kitchen Table Wisdom and My Grandfathers Blessings, Clinical Professor, Family and Community Medicine, UCSF. www.rachelremen.com